Investor Presentation

MedPlus Health Services Limited July 21, 2026 The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Fort, Bandra Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai – 400 051 BSE Scrip Code: 543427 NSE Symbol: MEDPLUS Dear Sir/ Madam, Sub: Presentation for Earnings Call with Analysts/Institutional Investors on Un-Audited Financial Results for the quarter ended June 30, 2026 Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our letter dated July 15, 2026 please find enclosed herewith the presentation for Earnings Call with Analysts/Institutional Investors on Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 scheduled to be held on Wednesday, July 22, 2026 at 16:00 Hrs. (IST). The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively. Thanking You Yours faithfully For MedPlus Health Services Limited Gangadi Madhukar Reddy Managing Director and CEO (DIN: 00098097) Encl: a/a 040-6724 6724 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com Performance – Q1 FY27 FY27 Q1 Executive Summary ➢ Revenue has grown by 21.8% from ₹ 15,426 million in Q1 FY26 to ₹ 18,796 million in Q1 FY27 ➢ During the quarter 146 new stores have been added (including 131 new franchisees) ➢ Gross margin decreased by 160 bps from 26.1% in Q1 FY26 to 24.5% in Q1 FY27 ➢ Operating EBITDA has decreased from ₹ 728 million in Q1 FY26 to ₹ 651 million in Q1 FY27 ➢ Operating EBITDA margin for Q1 FY27 has decreased by 120 bps YoY from 4.7% to 3.5% ➢ AOP vs Actual – Revenue ₹ 18,796 million / ₹ 18,993 million (99.0% achievement) ➢ AOP vs Actual – Op. EBITDA ₹ 651 million / ₹ 798 million (81.6% achievement) Income Statement : All Segments ₹m Q1 FY27 AOP Particulars Q1 FY27 Q1 FY26 Q4 FY26 YoY QoQ AOP Variance Revenue 18,796.0 15,426.3 18,643.8 18,993.5 21.8% 0.8% -1.0% - Revenue for Q1FY27 has grown by 21.8% YoY and QoQ has grown by 0.8% Gross Margin 4,603.1 4,029.0 4,934.4 4,913.9 14.3% -6.7% -6.3% Gross Margin% 24.5% 26.1% 26.5% 25.9% -1.6% -2.0% -1.4% - Gross margin % decreased by 160 bps YoY from 26.1% in Q1FY26 to 24.5% in Q1FY27 Shoplevel Expenses 2,695.7 2,365.4 2,595.4 2,817.7 14.0% 3.9% -4.3% Salaries 1,221.5 941.2 1,120.6 1,248.0 29.8% 9.0% -2.1% - Gross margin % decreased by 200 bps QoQ from 26.5% in Q4FY26 to 24.5% in Q1FY27 Rent 609.5 532.3 588.6 620.6 14.5% 3.5% -1.8% Others 864.7 891.9 886.1 949.1 -3.0% -2.4% -8.9% - Operating EBITDA Margin decreased by 130 bps YoY from 4.7% in Q1FY26 to 3.5% in Q1FY27 Shoplevel EBITDA 1,907.4 1,663.6 2,339.0 2,096.1 14.7% -18.5% -9.0% Shoplevel EBITDA% 10.1% 10.8% 12.5% 11.0% -0.6% -2.4% -0.9% - Operating EBITDA Margin decreased by 230 bps QoQ from 5.8% in Q4FY26 to 3.5% in Q1FY27 Other Expenses 1,256.2 935.5 1,262.7 1,298.0 34.3% -0.5% -3.2% PSD 794.5 583.4 751.3 786.3 36.2% 5.8% 1.0% Corporate 413.5 347.5 474.2 459.6 19.0% -12.8% -10.0% Marketing 16.8 15.8 29.3 30.0 6.0% -42.8% -44.1% Others 31.4 (11.3) 8.0 22.1 -378.9% 295.3% 42.1% Operating EBITDA 651.2 728.1 1,076.3 798.1 -10.6% -39.5% -18.4% Operating EBITDA% 3.5% 4.7% 5.8% 4.2% -1.3% -2.3% -0.7% EBITDA 1,530.7 1,457.6 1,897.7 1,647.9 5.0% -19.3% -7.1% PBT 418.8 527.8 803.4 536.7 -20.7% -47.9% -22.0% PBT% 2.2% 3.4% 4.3% 2.8% -1.2% -2.1% -0.6% PAT 331.7 423.5 639.7 401.7 -21.7% -48.2% -17.4% PAT% 1.8% 2.7% 3.4% 2.1% -1.0% -1.7% -0.4% Income Statement : Pharmacy ₹m Q1 FY27 AOP Particulars Q1 FY27 Q1 FY26 Q4 FY26 YoY QoQ AOP Variance - Revenue for Q1FY27 has grown by 21.8% YoY and QoQ Revenue 18,398.7 15,106.4 18,265.9 18,599.6 21.8% 0.7% -1.1% has grown by 0.7% Gross Margin 4,282.0 3,772.6 4,627.5 4,597.2 13.5% -7.5% -6.9% - Gross margin % decreased by 170 bps YoY from 25.0% in Q1FY26 to 23.3% in Q1FY27. Gross Margin% 23.3% 25.0% 25.3% 24.7% -1.7% -2.1% -1.4% - Decrease of 120 bps is due to lower sales mix of Private Label products and Shoplevel Expenses 2,498.0 2,201.3 2,403.6 2,616.2 13.5% 3.9% -4.5% - Decrease of 50 bps is due to lower margin realized Salaries 1,149.8 887.8 1,050.7 1,173.9 29.5% 9.4% -2.1% in franchisee business Rent 572.3 503.1 551.9 583.6 13.7% 3.7% -1.9% Others 775.9 810.4 801.1 858.6 -4.3% -3.1% -9.6% - Gross margin % decreased by 210 bps QoQ from 25.3% in Q4FY26 to 23.3% in Q1FY27 - Decrease of 100 bps is due to lower sales mix of Shoplevel EBITDA 1,784.1 1,571.3 2,223.9 1,981.1 13.5% -19.8% -9.9% Private Label products Shoplevel EBITDA% 9.7% 10.4% 12.2% 10.7% -0.7% -2.5% -1.0% - Decrease of 70 bps is due to lower inventory loss in the previous quarter Other Expenses 1,196.0 881.1 1,202.0 1,220.6 35.7% -0.5% -2.0% - Decrease of 40 bps is due to year end related PSD 761.7 554.0 719.2 745.1 37.5% 5.9% 2.2% supplier discounts received in the previous quarter Corporate 389.0 326.4 449.0 429.0 19.2% -13.4% -9.3% - Operating EBITDA Margin decreased by 140 bps YoY from Marketing 13.4 12.0 25.6 25.0 11.6% -47.4% -46.2% 4.6% in Q1FY26 to 3.2% in Q1FY27 Others 31.9 ( 11.3) 8 .3 21.6 -382.8% 284.5% 47.8% - Operating EBITDA Margin decreased by 240 bps QoQ Operating EBITDA 588.1 690.1 1,021.8 760.4 -14.8% -42.4% -22.7% from 5.6% in Q4FY26 to 3.2% in Q1FY27 Operating EBITDA% 3.2% 4.6% 5.6% 4.1% -1.4% -2.4% -0.9% Revenue by category ₹ million Particulars FY25Q1 FY25Q2 FY25Q3 FY25Q4 FY25 FY26Q1 FY26Q2 FY26Q3 FY26Q4 FY26 FY27Q1 Branded Pharma 10,333 10,594 10,330 9,543 40,800 9 ,987 10,736 11,245 11,598 43,566 11,981 Branded Non Pharma 1,672 1,679 1,620 1,424 6 ,395 1 ,421 1,463 1,627 1,634 6 ,146 1 ,665 Pvt Label Pharma 1,357 1,663 1,774 2,043 6 ,837 1 ,976 2,031 2,101 2,115 8 ,223 2 ,009 Pvt Label Non Pharma 1,004 1,240 1,291 1,463 4 ,997 1 ,347 1,621 1,908 1,979 6 ,855 1 ,754 Total 14,366 15,176 15,014 14,473 59,029 14,731 15,850 16,882 17,326 64,790 17,409 Franchisee and B2B 126 138 145 146 555 224 379 580 722 1 ,905 859 Others1 137 146 166 179 628 152 210 253 217 832 130 Grand Total 14,629 15,460 15,325 14,798 60,212 15,106 16,440 17,715 18,266 67,527 18,399 Others mainly include - Membership fee of Rs.97.6 million in FY27 Q1 (Rs.87.2 million in FY26 Q4) - Other charges collected Rs.9.0 million in FY27 Q1 (Rs.8.4 million in FY26 Q4) Category Mix (Net Sales) Particulars FY25Q1 FY25Q2 FY25Q3 FY25Q4 FY25 FY26Q1 FY26Q2 FY26Q3 FY26Q4 FY26 FY27Q1 Branded Pharma 71.9% 69.8% 68.8% 65.9% 69.1% 67.8% 67.7% 66.6% 66.9% 67.2% 68.8% Branded Non Pharma 11.6% 11.1% 10.8% 9.8% 10.8% 9.6% 9.2% 9.6% 9.4% 9.5% 9.6% Pvt Label Pharma 9.4% 11.0% 11.8% 14.1% 11.6% 13.4% 12.8% 12.4% 12.2% 12.7% 11.5% Pvt Label Non Pharma 7.0% 8.2% 8.6% 10.1% 8.5% 9.1% 10.2% 11.3% 11.4% 10.6% 10.1% Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 1. Others include Membership fee, Data fee, display income, etc. Market Estimates vs Performance ₹ million Axis Cap Nuvama Spark HDFC Sec Elara Cap MedPlus Revenue 1 8,512.0 18,203.0 18,737.0 18,510.0 18,112.0 18,796.0 Cost of sales 14,192.9 Gross Profit 4,603.1 Gross Margin % 24.5% Op.EBITDA 608.0 651.2 Op.EBITDA % 3.3% 3.1% 3.5% EBITDA 1,204.0 1,264.0 1,203.0 1,600.0 1,332.4 EBITDA margin 6.5% 6.9% 6.5% 8.8% 7.1% PBT 334.0 418.8 PAT 2 26.0 316.0 260.0 204.0 537.0 331.7 Network of 5,476 Pharmacies1… 5600 - Network of stores as on 30th June 2026 is 146 5476 5,476 (COCO stores 4,812 and Franchisee stores 664) 5400 218 5330 - Net addition of 146 stores in Q1FY27 5200 (Q1FY26 101) - Operating in 850+ Cities and towns, covering 5000 Kolkata 315 117 1 2,520+ PIN codes 4800 1 - Total Retail area is 2.9 Mn Sft with average 4712 store size is 528 Sft 4600 48 758 - Average [Showing first 8,000 characters — download PDF for full document]